This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
For instance, in the EU, 46 percent of genericmedicines from the EU Critical List of Medicines are provided by a single supplier. For these firms with over 60 percent market share, this number rises to 83 percent of critical genericmedicines, according to the data.
A controversial provision of a federal law designed to speed copycat drugs to market and foster competition saved Medicare Part D nearly $15 billion from 2015 to 2021 on just 15 medicines during that period, according to a new analysis.
drug shortages, a new white paper from German market analytics firm QYOBO supports the thesis that disproportionately low prices for genericmedicines can make it difficult for drugmakers to keep supplies afloat. . | As lawmakers and industry groups seek to get a handle on U.S.
The FTC is investigating wholesalers and other middlemen in the pharma supply chain to assess their possible role in worsening shortages of genericmedicines
patent system by the pharmaceutical industry, moves by some drugmakers to expand their patent claims appear to be delaying the arrival of lower-cost genericmedicines to the marketplace, according to a STAT analysis. Amid debate over potential abuse of the U.S.
In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a genericmedicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.
As a former editor for diabetes publications, I knew that insurance companies regularly switched people from one brand of insulin to another, or from a name brand of insulin to a generic. However, I had used genericmedicine for my blood pressure without a problem, so I hoped for the best with this switch.
Patent and Trademark Office has proposed a new rule designed to stem the use of so-called patent thickets , which are wielded by pharmaceutical companies to delay the arrival of lower-cost genericmedicines in the marketplace.
Specifically, the proposed rule was crafted to stem the use of so-called patent thickets , which are wielded by drug companies to delay the arrival of lower-cost genericmedicines in the marketplace.
Amid ongoing concern over the quality of medicines made in India, a major supplier of genericmedicines was seen removing three truckloads of “scrap materials” from a facility that was being inspected last month by the Food and Drug Administration.
In explaining its new policy statement , the FTC noted that some drug companies have failed to follow requirements for listing patents in the so-called Orange Book in hopes of thwarting competition from lower-cost genericmedicines.
Roared on by the pharmaceutical industry, ministers have been using trade talks with India to push for agreement on new, extremely restrictive patent rules that would severely undermine its genericmedicines industry.
A handful of the largest purveyors of genericmedicines have made only halting progress to ensure their drugs are accessible for patients in low- and middle-income countries, a new analysis found.
A growing number of alternative pharmacies — such as those run by Costco, Amazon, and Mark Cuban Cost Plus Drugs — may be increasingly popular with American consumers, but a new analysis finds many of the most expensive genericmedicines are unavailable, prices vary widely, and savings can be modest.
The move comes two months after the FTC issued a policy statement noting some drug companies have failed to follow requirements for listing patents in the Food and Drug Administration’s Orange Book in hopes of thwarting competition from lower-cost genericmedicines. Continue to STAT+ to read the full story…
A leaked draft version of a trade agreement being negotiated between the United Kingdom and India has sparked concern among civil society and patient advocacy groups that the proposed deal would impede the supply of affordable genericmedicines in poor countries around the world.
A leaked version of the agreement already sparked concerns last year that the proposed deal would impede the supply of affordable genericmedicines in poor countries around the world. More than 200 civil society and patient advocacy groups are urging the U.K. Now, the groups are upset that the involvement of Harjinder Kang, the U.K.
WASHINGTON — Generic drugmakers lobbied hard against Democrats’ new law empowering Medicare to negotiate prescription drug prices. Giving the government such power seemed like an admission that genericmedicines don’t do enough to keep costs down.
But it’s a genericmedicine — which means PBMs’ negotiating techniques don’t apply. Generic drugs compete on price. There’s just one problem: PBMs don’t have anything to do with that discrepancy. The chemo drug in question, Imatinib, costs $17,000 at CVS and just $72 at Cost Plus Drugs.
The review comes in response to an inspection of Synapse facilities by Spanish regulators, who raised “serious concerns about the validity and reliability” of clinical trial data generated by the company.
Europe also enforces rigid pricing policies for essential medicines to be available at the lowest possible price. These factors combined affect the commercial viability of genericmedicines, with some European drugmakers already warning that they may stop making cheap genericmedicines.
Two large Indian suppliers of genericmedicines in the U.S. and beyond are at the center of the industry's M&A rumor mill this week. Torrent is looking for financial help to potentially make a bid for its larger rival Cipla, according to Reuters.
Indian Medical Association says that testing is substandard in the manufacture of genericmedicines with ‘no guarantee of quality’ Indian doctors have been told they can no longer prescribe branded drugs for their patients, provoking vehement protest from the Indian Medical Association [IMA].
Ryzneuta (efbemalenograstim alfa) received a positive opinion from the CHMP as a medicine to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy. Additionally, a positive opinion for Niapelf (paliperidone), a genericmedicine for schizophrenia was adopted in the meeting.
The CJEU stressed that identical medicinal products are not those that are only therapeutically equivalent (as generics are to reference products), but they should be identical in all respects.
For Sandoz, the acquisition gives it a technology platform in an area of the genericmedicines market with a relatively high barrier to entry, as developing inhaled medicines poses “comparatively high technical complexity,” according to Sandoz chief executive Richard Saynor.
” It also sees continued growth in cardiovascular and venous diseases, as well as in genericmedicines, and says its new visual identity (see above) reflects its “uniqueness” as an “independent group, governed by a foundation, committed to therapeutic progress to serve patient needs.”
Over the same period, total gross expenditures on brand and genericmedicines nearly doubled – from $268 billion to $517 billion, according to the report.
Meanwhile, Sandoz would leverage its strong brand and sustain its leading global position by continuing to invest in the key strategic areas of Biosimilars, Antibiotics and GenericMedicines. Working to deliver on its vision of access to patients. Additional transaction details.
With the production of genericmedicine being concentrated in China and India, the ability to flexibly influence the supply of genericmedicine, which most antibiotics are, is relatively limited. Larger questions remain around the way in which to support manufacturers to invest in production capabilities for antibiotics.
Four new medicines recommended for approval The CHMP recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults. Sitagliptin/Metformin hydrochloride Sun (sitagliptin/metformin hydrochloride) for the treatment of type 2 diabetes mellitus.
The company offers genericmedicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others.
The small molecule API market is influenced by several factors, including heightened R&D within the pharmaceutical sector, a growing prevalence of chronic illnesses and rising demand for genericmedicines.
Last year, Sandoz generated sales worth $9.6bn and served more than 100 markets across the globe with a robust presence in the US, Europe and other regions. Upon becoming a standalone company, Sandoz would progress to make investments in the main strategic regions of antibiotics, biosimilars and genericmedicines.
We certainly have a problem with national-level procurement policies that put almost no value on genericmedicines … that approach needs to change. The rather inflexible, old-fashioned regulatory regime in Europe should be modernised in order to attract investment, and to improve agility and flexibility.”.
It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s genericmedicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US.
This combination inhaler is also available as a genericmedicine called fluticasone furoate and vilanterol , which are the names of the two medicines in the inhaler. Breo Ellipta is the brand name of an inhaler that contains two medications used to control asthma and COPD ( chronic obstructive pulmonary disease ).
Efforts by Amazon to disrupt the healthcare sector just stepped up a gear, with the launch of a subscription service for Prime members that will ship genericmedicines to patients’ homes in return for a $5 monthly fee.
. “As such, it is with great responsibility that I will take on the inspiring task to lead the company’s strong and unique R&D organisation, knowing that together with our scientists, researchers and staff we have a tremendous opportunity to bring meaningful specialty, biologics and genericsmedicines to patients worldwide.”
In recent years, first generics have improved patient access to essential treatments and offered affordable treatment options for patients with multiple sclerosis, asthma, heart disease, diabetes, and even the flu.
Astellas has won a reprieve in its attempt to stop Pfizer’s genericmedicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a couple of weeks.
The company offers genericmedicines and biosimilars through Sandoz. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others.
These medicines were recommended by the CHMP to treat plaque psoriasis, paediatric plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease. Tuznue (trastuzumab) for breast and gastric cancer.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content